FindTrial
Sign In

Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter Study

Clinical Outcomes and Prognostic Factors to Predict Treatment Response in High Risk Neuroblastoma Patients Receiving Topotecan and Cyclophosphamide Containing Induction Regimen: A Prospective Multicenter Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20190602002
Enrollment
Unknown
Registered
2019-06-02
Start date
2019-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study is an observational study and aims to evaluate the clinical outcomes and classify relevant prognostic factors to measure induction response among high risk neuroblastoma patients in Thailand high risked neuroblastoma&#44

Interventions

All high risk neuroblastoma patients who received topotecan and cyclophosphamide containing chemotherapy regimen as per ThaiPOG high risk neuroblastoma protocol between 2016&#45
2017
Treatment
Neuroblastoma patients

Sponsors

Phramongkutklao Hospital and College of Medicine
Lead Sponsor
The Patronage of Her Royal Highness Princess Soamsawali
Collaborator

Eligibility

Sex/Gender
All
Age
0 Years to 18 Years

Inclusion criteria

Inclusion criteria: The study’s inclusion criteria include patients less than 18 years of age who had a new diagnosis of high risk neuroblastoma stratified as per the International Neuroblastoma Risk Group Staging System (INRGSS).

Exclusion criteria

Exclusion criteria: Patients contra-indicated for topotecan or receiving a diagnosis of refractory or relapsed neuroblastoma

Design outcomes

Primary

MeasureTime frame
Clinical outcomes of high risk neuroblastoma patients 2016-2017 Mean with standard deviation for continuous variables; frequency and percentage for categorical vari—

Secondary

MeasureTime frame
Prognostic factors to predict treatment response among neuroblastoma patients 2016-2017 Univariate and multivariate analyses ,Treatment related toxicity among neuroblastoma patients 2016-2017 Frequency and percentage for categorical variables—

Countries

Thailand

Contacts

Public ContactPiya Rujkijyanont

Phramongkutklao Hospital and College of Medicine

piya_rujk@yahoo.com091-003-4585

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026